Q4 2025 Earnings Call February 25, 2026 10:00 AM ESTCompany ParticipantsMichael Hall - Vice President of Investor ...
Delivered strong full year 2025 resultsCompleted Initial Public OfferingIntroduced full year 2026 guidanceFourth quarter net sales of $7.8 billion, an increase of 14.8%Fourth quarter net income of ...
Delivered strong full year 2025 resultsCompleted Initial Public OfferingIntroduced full year 2026 guidanceFourth quarter net sales of $7.8 billion, an increase of 14.8%Fourth quarter net income of $18 ...
CAMBRIDGE, Mass.-- (BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results